文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

血浆焦磷酸盐与慢性肾脏病血管钙化。

Plasma pyrophosphate and vascular calcification in chronic kidney disease.

机构信息

Renal Division, Department of Medicine, Emory University, Atlanta, GA, USA.

出版信息

Nephrol Dial Transplant. 2010 Jan;25(1):187-91. doi: 10.1093/ndt/gfp362. Epub 2009 Jul 24.


DOI:10.1093/ndt/gfp362
PMID:19633093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4326300/
Abstract

BACKGROUND: Pyrophosphate (PPi) is a potent inhibitor of vascular calcification and may be deficient in renal failure. We sought to determine whether plasma PPi is affected by dialysis or the mode of dialysis and whether it correlates with vascular calcification. METHODS: PPi was measured in plasma samples stored from a recent study of vascular calcification in 54 HD patients, 23 peritoneal dialysis (PD) patients and 38 patients with stage 4 chronic kidney disease (CKD). Calcification was quantified in a standardized section of the superficial femoral artery using computed tomography, and PPi was measured by enzyme assay, at both baseline and 1 year. RESULTS: Baseline plasma PPi was weakly correlated with age and serum phosphate, but not with alkaline phosphatase activity or other biochemical parameters, and did not differ between HD, PD and CKD patients. Both baseline calcification score and change in the calcification score at 1 year decreased with increasing quartiles of plasma PPi. In a multivariate analysis, plasma PPi was independently correlated with baseline calcification (P = 0.039) and the change in calcification (P = 0.029). CONCLUSION: Plasma PPi is negatively associated with vascular calcification in end-stage renal disease (ESRD) and CKD but is not affected by dialysis, the mode of dialysis or nutritional or inflammatory status. Although these data are consistent with an inhibitory effect of PPi on vascular calcification, further studies are needed to establish a causal role.

摘要

背景:焦磷酸盐(PPi)是血管钙化的有效抑制剂,在肾衰竭中可能缺乏。我们试图确定血浆 PPi 是否受透析或透析方式的影响,以及它是否与血管钙化有关。

方法:我们检测了最近一项血管钙化研究中 54 名血液透析(HD)患者、23 名腹膜透析(PD)患者和 38 名 4 期慢性肾脏病(CKD)患者的血浆样本中储存的 PPi。使用计算机断层扫描定量测量股浅动脉标准部位的钙化,并通过酶法在基线和 1 年时测量 PPi。

结果:基线时血浆 PPi 与年龄和血清磷酸盐呈弱相关,但与碱性磷酸酶活性或其他生化参数无关,并且在 HD、PD 和 CKD 患者之间没有差异。基线钙化评分和 1 年时钙化评分的变化均随血浆 PPi 四分位的增加而降低。在多变量分析中,血浆 PPi 与基线钙化(P = 0.039)和钙化变化(P = 0.029)独立相关。

结论:在终末期肾病(ESRD)和 CKD 中,血浆 PPi 与血管钙化呈负相关,但不受透析、透析方式或营养或炎症状态的影响。尽管这些数据与 PPi 对血管钙化的抑制作用一致,但仍需要进一步研究以确定其因果关系。

相似文献

[1]
Plasma pyrophosphate and vascular calcification in chronic kidney disease.

Nephrol Dial Transplant. 2009-7-24

[2]
Vascular calcification and cardiovascular function in chronic kidney disease.

Nephrol Dial Transplant. 2006-3

[3]
Reduced plasma pyrophosphate levels in hemodialysis patients.

J Am Soc Nephrol. 2005-8

[4]
Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia.

Nephrol Dial Transplant. 2011-3-11

[5]
Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?

J Am Coll Cardiol. 2002-2-20

[6]
Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease.

Clin J Am Soc Nephrol. 2007-11

[7]
Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis.

Am J Nephrol. 2007

[8]
Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.

PLoS One. 2018-7-3

[9]
Association of conjunctival and corneal calcification with vascular calcification in dialysis patients.

Am J Kidney Dis. 2005-3

[10]
The importance of fetuin-A in vascular calcification in children with chronic kidney disease.

Adv Clin Exp Med. 2019-4

引用本文的文献

[1]
Early pharmacological blockade of the CXCL12-CXCR4 axis attenuates vertebral hypercalcification in a zebrafish model of pseudoxanthoma elasticum.

Biochem Biophys Rep. 2025-8-25

[2]
Recombinant ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) decreases vascular calcification and prevents osteomalacia in a rat model of chronic kidney disease.

JBMR Plus. 2025-4-16

[3]
Pharmacokinetics and Safety of Oral Pyrophosphate in Systemic Sclerosis Patients-A Pilot Study.

ACR Open Rheumatol. 2025-4

[4]
Phosphate in Cardiovascular Disease: From New Insights Into Molecular Mechanisms to Clinical Implications.

Arterioscler Thromb Vasc Biol. 2024-3

[5]
The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult-Onset Hypophosphatasia.

JBMR Plus. 2023-11-20

[6]
Humoral and cellular factors inhibit phosphate-induced vascular calcification during the growth period.

J Clin Biochem Nutr. 2023-11

[7]
ENPP1 in Blood and Bone: Skeletal and Soft Tissue Diseases Induced by ENPP1 Deficiency.

Annu Rev Pathol. 2024-1-24

[8]
Pathophysiology and Clinical Impacts of Chronic Kidney Disease on Coronary Artery Calcification.

J Cardiovasc Dev Dis. 2023-5-10

[9]
Weighing the Evidence for the Roles of Plasma Versus Local Pyrophosphate in Ectopic Calcification Disorders.

J Bone Miner Res. 2023-4

[10]
A new enzymatic assay to quantify inorganic pyrophosphate in plasma.

Anal Bioanal Chem. 2023-1

本文引用的文献

[1]
Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification.

Kidney Int. 2008-5

[2]
Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease.

Clin J Am Soc Nephrol. 2007-11

[3]
The fallacy of the calcium-phosphorus product.

Kidney Int. 2007-10

[4]
Vascular calcification and cardiovascular function in chronic kidney disease.

Nephrol Dial Transplant. 2006-3

[5]
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.

Kidney Int. 2005-10

[6]
Reduced plasma pyrophosphate levels in hemodialysis patients.

J Am Soc Nephrol. 2005-8

[7]
Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis.

Am J Kidney Dis. 2004-9

[8]
Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin.

J Am Soc Nephrol. 2004-6

[9]
Determinants of progressive vascular calcification in haemodialysis patients.

Nephrol Dial Transplant. 2004-6

[10]
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

Kidney Int. 2002-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索